S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
about
Melanoma-restricted genesInvestigation of cAMP microdomains as a path to novel cancer diagnosticsIn vitro screening and structural characterization of inhibitors of the S100B-p53 interactionStructure-Based Discovery of a Novel Pentamidine-Related Inhibitor of the Calcium-Binding Protein S100BCEACAM1: Expression and Role in Melanocyte TransformationCSF biomarkers for improved prognostic accuracy in acute CNS disease.Complex formation between S100B protein and the p90 ribosomal S6 kinase (RSK) in malignant melanoma is calcium-dependent and inhibits extracellular signal-regulated kinase (ERK)-mediated phosphorylation of RSKHumoral autoimmune responses to insulin-like growth factor II mRNA-binding proteins IMP1 and p62/IMP2 in ovarian cancer.Simultaneous inhibition of key growth pathways in melanoma cells and tumor regression by a designed bidentate constrained helical peptideRole of serum S100B and PET-CT in follow-up of patients with cutaneous melanomaAdipocytes as an Important Source of Serum S100B and Possible Roles of This Protein in Adipose Tissue.Alternatively spliced RAGEv1 inhibits tumorigenesis through suppression of JNK signalingCirculating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survivalMolecular determinants of S100B oligomer formationPrimary blast-induced traumatic brain injury in rats leads to increased prion protein in plasma: a potential biomarker for blast-induced traumatic brain injuryUse of proteins as biomarkers and their role in carcinogenesis.DAMPs, ageing, and cancer: The 'DAMP Hypothesis'.Human eosinophils express RAGE, produce RAGE ligands, exhibit PKC-delta phosphorylation and enhanced viability in response to the RAGE ligand, S100BSerum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients.The use of matrix coating assisted by an electric field (MCAEF) to enhance mass spectrometric imaging of human prostate cancer biomarkers.Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694.Molecular dynamic simulation insights into the normal state and restoration of p53 function.Target binding to S100B reduces dynamic properties and increases Ca(2+)-binding affinity for wild type and EF-hand mutant proteins.The tumour microenvironment and implications for cancer immunotherapy.Osteosarcoma development and stem cell differentiationLoss of S100 antigenicity in metastatic melanoma.Autoantibodies as biomarkers for ovarian cancer.Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.S100B Protein as a Post-traumatic Biomarker for Prediction of Brain Death in Association With Patient Outcomes.Transcriptomic Analysis of the Claudin Interactome in Malignant Pleural Mesothelioma: Evaluation of the Effect of Disease Phenotype, Asbestos Exposure, and CDKN2A Deletion Status.S100B protein in neurodegenerative disorders.Could serum measurements of S100 proteins be reliable markers to predict recurrence in meningiomas?Protein and non-protein biomarkers in melanoma: a critical update.The evolution of S100B inhibitors for the treatment of malignant melanoma.Biomarker analysis for oncology.Tumor-derived factors modulating dendritic cell function.Behaviour of four different B16 murine melanoma cell sublines: C57BL/6J skin.Protumorigenic actions of S100A2 involve regulation of PI3/Akt signaling and functional interaction with Smad3.Evaluation of melanogenesis in A-375 melanoma cells treated with 5,7-dimethoxycoumarin and valproic acid.Detection of melanoma-derived cancer-testis antigen CT16 in patient sera by a novel immunoassay.
P2860
Q24793788-05B7A1C2-49C6-4F47-B9F8-266F75E74483Q27023080-7B685BF0-CB5C-40FA-AA98-0B4B2ADF6AB2Q27666186-030B1F14-D82C-4761-B1A9-5128F6DF3269Q27675592-3D572812-C2EA-4B34-821E-2DD64CBA8A5EQ28072724-A9BC3C56-F946-42FD-ADF8-C84B2A37059BQ33313220-FF110F6B-431D-4528-BB03-0576A41F465CQ33556286-BC014D30-6B3A-4D77-9EFF-0E771FE36667Q33608271-677EC461-A683-4A43-8A24-62D660B945B2Q33934743-028F9A0B-6D87-48FB-9221-D5060882BD96Q33978914-6D00E421-F6AB-4E37-8199-51FC43E8994CQ34002819-336B1DBF-B17D-4FC0-9645-2F7CA2DFF5EDQ34056610-85FB3198-6D25-455A-9CDF-4B006BA61E59Q34170421-B902037D-72AA-420D-956C-8548D82D48CAQ34698701-0B2A88B2-BA7F-40EC-849A-8D4D5E930D13Q34751215-3BF66D47-F4B6-478E-9A18-97873827330EQ34784895-94B681B8-DCA9-4A48-BEDF-4F880EFABF0EQ35558632-6ED9D2BD-B3F7-4C0B-946B-C3C937F87F3AQ35579991-4B942814-BAD4-43D2-B61B-ADBCD86CDFBFQ35691891-391C07A1-0989-4A36-8DF7-7A4EDB0A10CDQ35891644-2990E93F-4585-4B3E-A069-9675BE4E3695Q36186934-BBF0D086-1D31-4D9D-9843-29F740EC2BFFQ36202281-57A59F5F-F03A-4160-81EB-57D69DFD9390Q36291452-A46D0293-D176-4A7A-B085-15E152839526Q36521830-6FBB3ADD-11A6-41A1-81AA-700B5F23836AQ36803600-D8433C4D-AE5A-4066-A1B1-2E11D2DE9444Q37129939-5C154AE8-7C6C-46A2-AB63-F3A0D1363403Q37224335-33F721E9-A399-4B22-BD15-2EE9F42F9DC2Q37383509-8DC94D2D-E1C2-4956-B2B9-F9032F88E963Q37422113-1EE3F81E-DC13-4B9A-BA9A-DBF80C68EE4EQ37712647-10A9FC56-67F9-420C-BFAE-1BD072D4A797Q37837904-CCC4971C-A331-4F70-8B86-7C7684DABA9FQ37851511-945B3334-DE40-468E-8270-3D056607175DQ38050990-9BBD1B20-AF2E-4BEE-9B85-CD5054C1B5E0Q38068971-7FD80F5D-7E05-4D4E-9A6C-67F13DDCCA90Q38578640-2CBF0059-ABEC-4156-99C1-922DB266E9E4Q38777795-E86BFEAD-BF68-4F7F-A692-E6B68BDC092BQ38911551-027EAB79-2F51-40FE-8610-FE6F999B1B6FQ39101381-64DB1644-E79D-4E0C-A23E-11200C4849CFQ39273391-FE0FE568-E610-4F44-90D2-25A5C4D95386Q39675961-2CEBF332-D2DD-4300-991E-13BDB2D169C4
P2860
S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
@ast
S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
@en
S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
@nl
type
label
S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
@ast
S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
@en
S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
@nl
prefLabel
S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
@ast
S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
@en
S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
@nl
P1476
S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
@en
P2093
Riikka Harpio
Roland Einarsson
P304
P356
10.1016/J.CLINBIOCHEM.2004.05.012
P577
2004-07-01T00:00:00Z